ストックスクリーナーアプリを入手
10.20
3.36%
0.37
Regenxbio Inc (RGNX) 最新ニュース
REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights - Citizen Tribune
REGENXBIO Inc. (NASDAQ:RGNX) Shares Fly 34% But Investors Aren't Buying For Growth - simplywall.st
BlackRock, Inc. Reduces Stake in Regenxbio Inc: A Strategic Port - GuruFocus
REGENXBIO to Host Conference Call on May 12 to Discuss First Qua - GuruFocus
REGENXBIO Q1 2025 Earnings Call: Financial Results and Key Operations Update Coming May 12 - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
Regenxbio Inc’s Market Journey: Closing Weak at 5.93, Down -5.72 - DWinneX
Is REGENXBIO (NASDAQ:RGNX) A Risky Investment? - simplywall.st
REGENXBIO Inc. (NASDAQ:RGNX) Shares Bought by Geode Capital Management LLC - Defense World
Form 8-KCurrent report - ADVFN
Regenxbio (RGNX) Gains Following Positive FDA Comments on Gene Therapies - GuruFocus
Vanguard Group Inc. Trims Stake in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat
RGNX stock touches 52-week low at $5.6 amid sharp annual decline - Investing.com Nigeria
RGNX stock touches 52-week low at $5.6 amid sharp annual decline By Investing.com - Investing.com South Africa
When (RGNX) Moves Investors should Listen - news.stocktradersdaily.com
Clear Street sets Regenxbio stock Buy rating, $50 target By Investing.com - Investing.com Australia
Clear Street sets Regenxbio stock Buy rating, $50 target - Investing.com India
5 Reasons To Buy Regenxbio Right Now (NASDAQ:RGNX) - Seeking Alpha
REGENXBIO partners with Nippon Shinyaku for MPS therapies - MSN
Regenxbio’s Triple Threat: Partnered Programs, DMD Progress And In-House Manufacturing - insights.citeline.com
RegenXBio Positioned Favorably Amid Competitor Safety Concerns, Justifying Buy Rating - TipRanks
REGENXBIO’s DMD Gene Therapy RGX-202 Generates Microdystrophin Expression in Additional Patients Treated in Phase 1/2 Trial - CGTLive™
Regenxbio Rises After Duchenne Update And Sarepta Safety Scare - insights.citeline.com
Sarepta safety update on Elevidys boosts Regenxbio, hurts Solid Bio - MSN
Regenxbio’s RGX-202 continues to show promise in DMD - The Pharma Letter
Regenxbio’s DMD gene therapy drives 122.3% biomarker uptick in three-year-old - Clinical Trials Arena
Regenxbio stock target raised to $29 at Raymond James By Investing.com - Investing.com Canada
REGENXBIO reports promising gene therapy trial results By Investing.com - Investing.com South Africa
Baird maintains Regenxbio stock outperform rating, $39 target By Investing.com - Investing.com South Africa
Baird maintains Regenxbio stock outperform rating, $39 target - Investing.com
Regenxbio stock target raised to $29 at Raymond James - Investing.com India
Regenxbio up 4% following additional data on Duchenne gene therapy asset - MSN
Regenxbio Touts Positive Biomarker Data From Duchenne Muscular Dystrophy Gene Therapy Trial - Benzinga
Regenxbio Says New Data Support Potential Gene Therapy for Duchenne Muscular Dystrophy - MarketScreener
REGENXBIO reports promising gene therapy trial results - Investing.com India
REGENXBIO: New Interim Data Reinforces Potential Of RGX-202Quick Facts - Nasdaq
Breakthrough: REGENXBIO DMD Gene Therapy Achieves Unprecedented 122% Protein Expression - StockTitan
Regenxbio stock up, Solid Bio down post Sarepta update (RGNX) - Seeking Alpha
Regenxbio at UBS Virtual CNS Day: Gene Therapy Advancements - Investing.com
Regenxbio at UBS Virtual CNS Day: Gene Therapy Advancements By Investing.com - Investing.com Canada
H.C. Wainwright cuts Regenxbio stock target to $34, maintains buy By Investing.com - Investing.com Philippines
REGENXBIO Inc. (NASDAQ:RGNX) Is About To Turn The Corner - Yahoo Finance
H.C. Wainwright cuts Regenxbio stock target to $34, maintains buy - Investing.com India
0.33%
2.46%
大文字化:
|
ボリューム (24 時間):